It is a parent’s nightmare: a child is born apparently healthy, then stops meeting developmental milestones at one year old. Her verbal and motor skills vanish, and irregular breathing, seizures, and a host of other problems appear. The cause is Rett syndrome—a devastating genetic, neurologic disorder that typically affects girls, resulting in severe disability and often accompanied by autistic behavior. Most Rett patients will live into middle age and require specialized full-time care. There is no cure, but researchers from Case Western Reserve University School of Medicine have been working to find ways to restore brain function and reverse disabilities associated with Rett syndrome.
In a recent study, researchers identified a specific brain region—the medial prefrontal cortex—as being particularly important for some of the respiratory and cognitive abnormalities seen in Rett syndrome. The study used a Rett mouse model to show activating neurons in this region can reverse breathing and memory abnormalities in symptomatic animals.
The team studied mice harboring a defect in the gene that causes Rett syndrome in humans. In the mouse model, they found neurons in the medial prefrontal cortex are relatively inactive, because they lack adequate stimulation from other nerve cells. The researchers hypothesized that low activity levels in these neurons could be causing Rett symptoms. By using molecular manipulations, the researchers specifically activated the “sleeping” neurons. The procedure restored normal breathing in the mice and reversed a specific deficit in long-term memory.
“‘Waking up’ these neurons, or increasing their electrical activity, results in a reversal of disease symptoms. With respect to the behaviors we studied, we can literally switch the animals from the disease state to the normal state (and back) by waking up (or not) these neurons,” explained study lead David M. Katz, PhD, professor of neurosciences and psychiatry at Case Western Reserve University School of Medicine. “Thus, despite the severity of Rett syndrome, brain circuits in affected animals are sufficiently intact that, with appropriate manipulation, their functionality can be rescued and normal behavior restored.” The results are part of the PhD thesis research of James Howell, a graduate student in the Katz laboratory.
The findings suggest stimulating neurons in the medial prefrontal cortex might also be therapeutic for Rett patients. Researchers hope it could help normalize breathing and improve cognitive function. The same approach, applied to other brain regions, could potentially lead to other improvements, such as enhanced motor function.
Such therapies could also benefit other patients. According to the authors, Rett syndrome is one of the most physically debilitating disorders on the autism spectrum and is seen as a potential model for other types of autism. Said Katz, “Whatever we learn about what is wrong in the Rett brain, and how to treat this disorder, may be of benefit not only to Rett patients, but others on the spectrum as well.”
Katz is now working to specifically define the subsets of neurons in the Rett brain that need to be activated to reverse symptoms. “This will hopefully make it possible to design more precise therapeutic strategies,” Katz said. His team is also looking at ways to translate their mouse model findings into potential treatments for Rett patients.
The study appeared in eNeuro, the official online journal of the Society for Neuroscience. Last month, Katz was a panelist at a conference sponsored by the National Institute of Neurological Disease and Stroke on advancing therapies for neurodevelopmental disorders. He was also recently interviewed about advances in Rett syndrome research in Chemical and Engineering News, the weekly magazine of the American Chemical Society.
For more information about Case Western Reserve University School of Medicine, please visit: case.edu/medicine.
Howell, et al. “Activation of the Medial Prefrontal Cortex Reverses Cognitive and Respiratory Symptoms in a Mouse Model of Rett Syndrome.” eNeuro. 21 Dec 2017, 4(6). doi: https://doi.org/10.1523/ENEURO.0277-17.2017.
Katz is a co-founder of ArRETT Neuroscience, a company focused on advancing treatments for patients with Rett syndrome and related disorders. This work was supported by National Institute of Neurological Disorders and Stroke Grants NS057398 (to D.M.K.) and NS098574-02 (to C.J.H.).
Associate Communications Specialist
Case Western Reserve University
School of Medicine